Biotricity has selected AT&T as its prefered network partner, providing the wireless carrier entry into the medical market.
AT&T has a pilot program in place that provides Biotricity with “near real-time connectivity for data transmission.” That will expand to a full program later this year, when Biotricity launches its first wearable.
See Also: IoT revenues up 15%; cloud computing a big driver
Bioflux, the name of the wearable, enables physicians to diagnose cardiovascular and coronary heart disease (CVD and CHD) by monitoring the person for 30 days and sending results back in real-time.
Having the system send back data in real-time is important, as it may inform physicians or doctors that the patient is in cardiac distress.
Biotricity also plans a new wearable
Biotricity also plans to sell Biolife, a personal wearable for people to track heart-rhythm, respiration, calories, temperature, physical activity, and other measurements. Users will receive support from physicians, but its unclear if data will be sent in real-time to a physician.
“For medical device manufacturers to successfully enter and establish themselves in the new connected healthcare industry, it is imperative that they look beyond traditional forms of technological innovation,” said Biotricity founder and CEO Waqaas Al-Siddiq. “IoT, for example, would be an avenue for consideration. Medical device manufacturers are uniquely positioned to be successful in this market, as they have a profound understanding of the regulatory process, critical applications, and patient risk.”
Biotricity is attempting to hit two surging markets, IoT and personal healthcare, at the same time. It has went through the regulatory process of getting the device approved by the FDA as well, something traditional tech firms like Apple and Fitbit have struggle with in the past.
The question now is can Biotricity win over physicians and consumers, the former may be inclined to stick with current methods, the latter may be happy enough with their Fitbit or Apple Watch health services.